Sarcomas | Specialty

Trabectedin Extends PFS in Phase III Soft Tissue Sarcoma Study

June 3rd 2015

Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.

Eribulin Elicits Survival Advantage in Phase III Sarcoma Study

May 31st 2015

Treatment with eribulin (Halaven) improved overall survival by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma and adipocytic sarcoma.

Eribulin Extends Survival in Phase III Sarcoma Study

February 25th 2015

Treatment with eribulin mesylate significantly extended overall survival compared with dacarbazine in patients with advanced soft tissue sarcoma.

Lung Cancer Screening, Trabectedin in Soft Tissue Sarcoma, and More

February 12th 2015

Palbociclib: An Exciting New Option in Breast Cancer

February 12th 2015

Integrating Palbociclib Into the Treatment of Breast Cancer

February 12th 2015

Preclinical and Clinical Evidence Supporting Palbociclib

February 12th 2015

Trabectedin Receives Priority Review for Advanced Soft Tissue Sarcoma

February 3rd 2015

The FDA has granted a priority review to trabectedin (Yondelis) to treat patients with advanced soft tissue sarcoma.

Dr. Van Tine Discusses Potential Novel Treatment Modalities for Sarcoma

July 23rd 2014

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

Dr. Movva on Molecular Profiling in Sarcoma

July 16th 2014

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.

Patient's Twenty-Pound Tumor Sheds Light on Liposarcoma - A Rare Form of Soft Tissue Cancer

July 14th 2014

Surgical Team at NYU Langone Medical Center Successfully Removes Life-Threatening Retroperitoneal Mass Along with Several Organs -- Staten Island Resident Expresses His Thanks

Dr. Tap on Combined KIT and CTLA-4 Blockade in Patients with GIST

July 10th 2014

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the idea of using combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS

May 14th 2014

The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.

Discovery Dilemma: Narrow "Superiority" Standard Is an Inferior Way to Evaluate Novel Therapies

February 27th 2014

The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.

Dr. Keedy Discusses Imaging Biomarkers in Osteosarcoma

January 6th 2014

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.

Novel Imaging Identifies Changes in Osteosarcoma Earlier in Treatment

December 23rd 2013

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

Updated Results Confirm Aldoxorubicin Superiority in STS

December 19th 2013

Aldoxorubicin demonstrated significant benefit to progression-free survival (PFS) compared with doxorubicin in patients with first-line, metastatic, locally advanced or unresectable soft tissue sarcomas

Early Data Show Patients With STS May Benefit From Belinostat

November 26th 2013

Final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial analyzing belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS) demonstrated that the novel agent could provide benefit in this space

Aldoxorubicin More Effective Than Doxorubicin in Soft Tissue Sarcomas

November 22nd 2013

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared to doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas.

Eribulin Shows Promise in Pediatric Sarcomas

November 21st 2013

Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.